Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Wockhardt Ltd

| Q4 FY26 Earnings Conference Call

BULLISH SENTIMENT

Report Source

⬤11th Jun 26

Summary : Wockhardt is transforming into an innovation-led company, buoyed by US FDA approval of its novel antibiotic Zaynich and strong financial turnaround, with global expansion plans.

Management Perspective positive : Management repeatedly expressed pride in the US FDA approval of Zaynich, highlighted significant financial improvements, and conveyed strong confidence in future growth from their R&D pipeline and strategic market entries. Phrases like 'journey of transformation has begun,' 'stronger, more focused,' and 'crowning achievement' indicate a highly optimistic outlook.

Concall Report Analysis & Insights

Business Overview

  1. Wockhardt is a global research-driven multinational organization with three main pillars.
  2. Pharmaceutical business comprises about 75% of total business.
  3. Biosimilar and biotech business grew 27%, scaling human insulin and Glargine production.
  4. Novel antibiotic business includes the recently US FDA-approved Zaynich.
  5. Reported INR3,373 crores top line, INR630 crores EBITDA (51% growth), and INR238 crores PBT.

Future Growth Prospects

  1. Global launch of Zaynich in US, India, Europe, and emerging markets.
  2. Scaling Emrok and Miqnaf franchises in India.
  3. Developing five new biosimilar products including Aspart and Semaglutide.
  4. Continued focus on operational excellence, talent development, and AI integration.
  5. Building a patient-centric business model for sustainable revenue growth.

Management Insights

  1. "Wockhardt's journey of transformation has begun; we have emerged stronger, more focused, and innovation-led."
  2. "We are now the first Indian company to have an Indian research product approved with the US FDA, Zaynich."
  3. "Our EBITDA margin has increased from 5.4% to 18.6% over the last three years due to focus on profitability."
  4. "We are challenging the conventional launch playbook of innovation by bringing Zaynich parallelly in US and India."
  5. "We believe Zaynich is a once-in-a-generation opportunity for patient impact and commercial success."

Signs of Skepticism

  1. Management did not provide specific revenue projections for Zaynich beyond a global peak sales range.
  2. The exit from the US generics market was attributed to unprofitability, but a question about potential conflict with patented products was not directly addressed.
  3. The timeline for European approval of Zaynich is uncertain, depending on regulatory processes.
  4. The company's ROCE target for the next 2-3 years was not explicitly stated.
  5. The long-term commercial success of Odrate compared to Zaynich was not definitively clarified.

Risk Factors

  1. Building a new business model for novel antibiotics is a significant challenge.
  2. The US market for new antibiotic launches is complex and requires specific strategies.
  3. Upfront costs for establishing the new antibiotic organization may lead to initial losses.
  4. Competition in the biosimilar space with many players.
  5. Ensuring market access and adoption for new drugs in diverse global markets.

Good To Know

  1. The company has 11 manufacturing facilities and two R&D centers.
  2. Exited loss-making US generic business and optimized supply chain.
  3. Implemented S/4HANA cloud version and integrating AI initiatives.
  4. Zaynich is the first Indian research product approved by US FDA.
  5. Zaynich covers 95% of carbapenem-resistant cases and has 96.8% composite cure rate in trials.

Key Drivers

  1. US FDA approval of novel antibiotic Zaynich.
  2. Global launch of Zaynich in key markets.
  3. Strong R&D pipeline with multiple biosimilars.
  4. Improved financial performance and profitability.

Key Analyst Discussions

Competitive Environment

  1. Zaynich is differentiated by its unique mechanism, hydrolyzing bacterial cell walls for rapid antibacterial effect.
  2. Zaynich's clinical trials showed 20% higher composite cure rate than Meropenem.
  3. The US market for new anti-infectives is estimated at $1 billion, with Wockhardt aiming for significant share.
  4. Zaynich is considered more effective and safer than competitor cefiderocol.
  5. Wockhardt has six molecules with QIDP status from US FDA, indicating strong R&D success.

Market Trends & Consumer Behavior

  1. Zaynich addresses the growing problem of multi-drug resistant gram-negative infections globally.
  2. High burden of carbapenem resistance in India, with 35-45% of gram-negative infections being resistant.
  3. Zaynich aims to reduce hospital readmission rates and length of stay, providing economic benefits.
  4. The company focuses on patient access and eliminating price as a barrier for Zaynich in India.
  5. Precision antibiotic stewardship is crucial for ensuring the right drug for the right patient.

Financial Highlights

  1. Capex for the next three years is projected at INR200-300 crores, primarily for biologicals capacity.
  2. R&D spends will continue at a similar percentage of sales.
  3. Initial 12-18 months for Zaynich launch may see a slight negative impact on profitability due to upfront costs.
  4. Expect to breakeven on Zaynich in 12-18 months, followed by a 'hockey stick' rise in profitability.
  5. Biosimilar business grew 35% last year and aims to double in 24-36 months.

Product Composition

  1. Zaynich is the primary novel antibiotic focus for global expansion.
  2. Emrok and Miqnaf are important for the India portfolio, with Foviscu expected to be filed soon.
  3. Biosimilar pipeline includes Aspart, RN 30/70, Degludec, and Semaglutide.
  4. Odrate is a once-a-day product for follow-on treatment outside hospitals, four years away.
  5. The company will stick to antibiotic research for the next 10 years, not chronic management.

Strategic Considerations

  1. The strategy for Zaynich launch in the US involves an operating partner for logistics and distribution.
  2. Wockhardt is building its own strong leadership and medical teams for US and India launches.
  3. The company aims for fast hospital penetration and deep clinical adoption in the US.
  4. India will serve as a blueprint for launching Zaynich in other emerging markets.
  5. Wockhardt's strategy is to build the business itself rather than relying on partnerships for novel antibiotics.